Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

Takashi Higuchi; Hiromichi Oshiro; Zhiying Zhang; Kentaro Miyake; Norihiko Sugisawa; Yuki Katsuya; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Kentaro Igarashi; Ming Zhao; Michael Bouvet; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M Hoffman

Translational Oncology (Apr 2019)

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

Takashi Higuchi,
Hiromichi Oshiro,
Zhiying Zhang,
Kentaro Miyake,
Norihiko Sugisawa,
Yuki Katsuya,
Norio Yamamoto,
Katsuhiro Hayashi,
Hiroaki Kimura,
Shinji Miwa,
Kentaro Igarashi,
Ming Zhao,
Michael Bouvet,
Shree Ram Singh,
Hiroyuki Tsuchiya,
Robert M Hoffman

Affiliations

Takashi Higuchi: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Hiromichi Oshiro: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Zhiying Zhang: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Kentaro Miyake: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Norihiko Sugisawa: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Yuki Katsuya: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA
Norio Yamamoto: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Katsuhiro Hayashi: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Hiroaki Kimura: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Shinji Miwa: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Kentaro Igarashi: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan
Ming Zhao: AntiCancer, Inc., San Diego, CA, USA
Michael Bouvet: Department of Surgery, University of California, San Diego, CA, USA; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.
Shree Ram Singh: Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.
Hiroyuki Tsuchiya: Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.
Robert M Hoffman: AntiCancer, Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Address all correspondence to: Michael Bouvet, Department of Surgery, University of California, San Diego, CA, USA. or Shree Ram Singh, Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. or Hiroyuki Tsuchiya, Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan. or Robert M Hoffman, AntiCancer, Inc., San Diego, CA, USA.

Journal volume & issue: Vol. 12, no. 4
pp. 640 – 645

Abstract

Read online

The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM). The NSCLC cell line PC-9 expressing green fluorescence protein (PC-9-GFP) was implanted in the brain of nude mice and was treated with CDDP + PEM or AZD9291. Tumors were observed by non-invasive fluorescence imaging. AZD9291 treatment caused tumor regression in contrast to CDDP + PEM which had only a slight inhibitory effect. These results suggest that AZD9291 is a promising clinical option for NSCLC patients with brain metastasis.

Published in Translational Oncology

ISSN: 1944-7124 (Print); 1936-5233 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/translational-oncology/

About the journal